NEOVACCINE STRATEGIES

Neovaccine Strategies develops a novel immunotherapeutic reagent to act as a prophylactic against P. aeruginosa. Its technique generates antibodies to the abundant, highly conserved protein EF-Tu. Encouraged by early findings, Neovaccine will test their vaccine on a mouse model in the next phase of development. This technique, the passive administration of antibodies, importantly does not require a functioning immune response, making this ideally suited to immunocompromised patients needing protection from this bacterial pathogen.